Sunitinib in a MEN-1 Patient with Small Cell Neuroendocrine Tumor of the Thymus Abstract #524

Introduction: MEN-1 is an autosomal dominant disease caused by mutation of the oncosuppressor gene menin. MEN-1 is typically associated with hyperparathyroidism, islet cell tumors and pituitary adenomas, but it can also be associated with other neoplasms, such as thymic carcinoids.
Aim(s): In January 2009, a 49-year old patient diagnosed with a small cell neuroendocrine tumor of the thymus, considered inoperable. From March 2009 to March 2011, she received several systemic anti-neoplastic therapy consisting of carboplatin-etoposide, capecitabine-gemcitabine, somatostatin analogues and Everolimus. In March 2011, the patient presented progressive radiographic disease with worsening of the mediastinal syndrome. In April 2011, she was started on Sunitinib as reported in a large phase III trial on neuroendocrine tumors of the pancreas. She quickly achieved symptomatic improvement. Stable disease was detected on PET-CT scan in July 2011, which was confirmed in December 2011 by PET-CT scan.
Materials and methods: Sunitinib 50 mg/daily, 4/2 w.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Prof Giovannella Palmieri

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result